Delta-9-tetrahydrocannabinol
Delta-9-tetrahydrocannabinol is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
Cannabis Effects on Driving-related Skills of Young Drivers
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids
Safety and Tolerability of Namisol in the Elderly
Clinical Trials (6)
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
Cannabis Effects on Driving-related Skills of Young Drivers
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids
Safety and Tolerability of Namisol in the Elderly
Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6